Nautilus Biotechnology, Inc. NAUT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

33/100

1/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Nautilus Biotechnology, Inc. (NAUT) has a negative trailing P/E of -6.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -14.84%.

Criteria proven by this page:

VALUE (20/100, Fail) — negative P/E indicates the company is currently operating at a loss — DCF and P/E-based valuation models cannot produce meaningful results for unprofitable companies (P/E -6.7); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY -14.84%); analyst consensus target implies downside from the current price ($2.50, 18.3%).
Trailing Earnings Yield -14.84% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $2.50 (-18.3% downside) — analysts see meaningful downside risk at the current price level.

Overall SharesGrow Score: 32/100 with 1/7 criteria passed.

SharesGrow 7-Criteria Score

33/100

SG Score

View full scorecard →

✗

VALUE

20/100

Price-to-Earnings & upside

Proven by this page

✗

FUTURE

37/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

28/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — NAUT

Valuation Multiples

P/E (TTM)-6.7

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio2.53

P/S Ratio0.00

EV/EBITDA-7.9

Per Share Data

EPS (TTM)$-0.47

Book Value / Share$1.24

Revenue / Share$0.00

FCF / Share$-0.41

Yields & Fair Value

Earnings Yield-14.84%

Dividend Yield0.00%

Analyst Target$2.50 (-18.3%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	Dividend Yield
2018	0.1	0.00	15.01	-
2019	-6.6	0.06	3.51	-
2020	-23.0	0.33	-12.07	-
2021	-8.7	-0.31	1.20	-
2022	-3.9	0.17	0.71	-
2023	-5.9	-0.54	1.41	-
2024	-3.0	-0.30	1.01	-
2025	-4.2	0.26	1.57	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2018	$87.18	$0.00	$626.6M	-
2019	$-1.59	$0.00	$-9.62K	-
2020	$-0.54	$0.00	$-15.62M	-
2021	$-0.60	$0.00	$-50.32M	-
2022	$-0.46	$0.00	$-57.92M	-
2023	$-0.51	$0.00	$-63.68M	-
2024	$-0.56	$0.00	$-70.78M	-
2025	$-0.47	$0.00	$-59M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-0.55	$-0.57 – $-0.53	$700K	$500K – $900K	2
2027	$-0.55	$-0.66 – $-0.44	$7.65M	$4.8M – $10.5M	2
2028	$-0.44	$-0.65 – $-0.23	$30M	$19.04M – $40.96M	1
2029	$-0.38	$-0.56 – $-0.20	$68.7M	$43.61M – $93.79M	1
2030	$-0.25	$-0.37 – $-0.13	$126.7M	$80.42M – $172.98M	1